PA8748101A1 - Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus - Google Patents
Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janusInfo
- Publication number
- PA8748101A1 PA8748101A1 PA20078748101A PA8748101A PA8748101A1 PA 8748101 A1 PA8748101 A1 PA 8748101A1 PA 20078748101 A PA20078748101 A PA 20078748101A PA 8748101 A PA8748101 A PA 8748101A PA 8748101 A1 PA8748101 A1 PA 8748101A1
- Authority
- PA
- Panama
- Prior art keywords
- treatment
- disease
- compounds
- preparation
- oxazolopiridins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA INVENCION SE REFIERE A COMPUESTOS DE BENZOXAZOL 2,7-DISUSTITUIDO Y OXAZOLO-[5,4-C]-PIRIDINA 2,4-DISUSTITUIDA DE LA FORMULA I QUE SE DA MAS ADELANTE, ASI COMO A SALES DE LOS MISMOS, A PROCESOS PARA SU PREPARACION, A LA APLICACION DE LOS MISMOS EN UN PROCESO PARA EL TRATAMIENTO DEL CUERPO HUMANO O ANIMAL, ESTOS COMPUESTOS PARA UTILIZARSE EN EL TRATAMIENTO (INCLUYENDO PROFILAXIS) DEL CUERPO DEL ANIMAL, EN ESPECIAL HUMANO (ESPECIALMENTE CON RESPECTO A UNA ENFERMEDAD PROLIFERATIVA), EL USO DE LOS MISMOS - SOLOS O EN COMBINACION CON UNO O MAS COMPUESTOS FARMACEUTICAMENTE ACTIVOS DIFERENTES - PARA EL TRATAMIENTO EN ESPECIAL DE UNA ENFERMEDAD MEDIADA POR LA CINASA DE PROTEINA TIROSINA (TAL COMO UNA ENFERMEDAD TUMORAL) O PARA LA FABRICACION DE UNA PREPARACION FARMACEUTICA PARA UTILIZARSE EN EL TRATAMIENTO DE ESTA ENFERMEDAD, UN METODO PARA EL TRATAMIENTO DE ESTA ENFERMEDAD Y UNA PREPARACION FARMACEUTICA PARA EL TRATAMIENTO DE UNA ENFERMEDAD COMO SE MENCIONA. LOS COMPUESTOS SON DE LA FORMULA I: EN DONDE LOS SIMBOLOS SON COMO SE DEFINEN EN LA DESCRIPCION. LOS COMPUESTOS INHIBEN, POR EJEMPLO, JAK2 Y JAK3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06120733A EP1900729A1 (en) | 2006-09-15 | 2006-09-15 | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8748101A1 true PA8748101A1 (es) | 2009-08-26 |
Family
ID=37717673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20078748101A PA8748101A1 (es) | 2006-09-15 | 2007-09-14 | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8629168B2 (es) |
| EP (2) | EP1900729A1 (es) |
| JP (1) | JP5325105B2 (es) |
| KR (1) | KR20090064389A (es) |
| CN (1) | CN101516860B (es) |
| AR (1) | AR062786A1 (es) |
| AT (1) | ATE532774T1 (es) |
| AU (1) | AU2007296916B2 (es) |
| BR (1) | BRPI0716841A2 (es) |
| CA (1) | CA2660987A1 (es) |
| CL (1) | CL2007002669A1 (es) |
| CO (1) | CO6150142A2 (es) |
| CR (1) | CR10639A (es) |
| EA (1) | EA200900388A1 (es) |
| ES (1) | ES2377148T3 (es) |
| GT (1) | GT200900056A (es) |
| IL (1) | IL196860A0 (es) |
| MA (1) | MA30723B1 (es) |
| MX (1) | MX2009002812A (es) |
| NO (1) | NO20091469L (es) |
| PA (1) | PA8748101A1 (es) |
| PE (1) | PE20080842A1 (es) |
| PL (1) | PL2066647T3 (es) |
| PT (1) | PT2066647E (es) |
| SM (1) | SMP200900023B (es) |
| TN (1) | TN2009000070A1 (es) |
| TW (1) | TW200819444A (es) |
| UY (1) | UY30587A1 (es) |
| WO (1) | WO2008031594A1 (es) |
| ZA (1) | ZA200900477B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
| MX2011000211A (es) * | 2008-07-15 | 2011-03-03 | Sanofi Aventis | Oxazolopirimidinas como agonistas del receptor edg-1. |
| JP2011530483A (ja) * | 2008-08-12 | 2011-12-22 | 武田薬品工業株式会社 | アミド化合物 |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| CN102227409B (zh) | 2008-11-28 | 2014-03-26 | 兴和株式会社 | 吡啶-3-甲酰胺衍生物 |
| WO2011078360A1 (ja) | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
| AR079980A1 (es) * | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de oxazolopirimidina sustituida en 2,5,7 |
| WO2012148540A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kanase inhibitors and uses threof |
| US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| US8907093B2 (en) * | 2011-07-07 | 2014-12-09 | Sanofi | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| CN103102359B (zh) * | 2011-11-15 | 2016-11-09 | 江苏先声药业有限公司 | 嘧啶类化合物及其应用 |
| WO2013082476A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| WO2014075318A1 (zh) * | 2012-11-19 | 2014-05-22 | 江苏先声药业有限公司 | 嘧啶类化合物及其应用 |
| CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
| CN103664759A (zh) * | 2013-12-06 | 2014-03-26 | 常熟市联创化学有限公司 | 一种3-羟基-2-硝基吡啶的制备方法 |
| JP6200603B2 (ja) | 2014-02-03 | 2017-09-20 | クワドリガ バイオサイエンシーズ， インコーポレイテッド | 化学療法剤としてのβ置換βアミノ酸および類似体 |
| JP6271766B2 (ja) | 2014-02-03 | 2018-01-31 | クワドリガ バイオサイエンシーズ， インコーポレイテッド | 化学療法剤としてのβ置換γアミノ酸および類似体 |
| WO2016047678A1 (ja) * | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017024009A1 (en) | 2015-08-03 | 2017-02-09 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
| WO2022251597A1 (en) | 2021-05-28 | 2022-12-01 | Verge Analytics, Inc. | Methods of treating neurological disorders with modulators of ribosomal protein s6 kinase alpha-1 (rsk1) and ribosomal protein s6 kinase alpha-3 (rsk2) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2208433T3 (es) * | 1999-12-10 | 2004-06-16 | Pfizer Products Inc. | Compuestos de pirrolo(2,3-d)pirimidina como inhibidores de proteina quinasas. |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| EP1674467A1 (en) * | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| ES2359431T3 (es) * | 2005-09-02 | 2011-05-23 | F. Hoffmann-La Roche Ag | Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. |
| WO2008009458A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
-
2006
- 2006-09-15 EP EP06120733A patent/EP1900729A1/en not_active Ceased
-
2007
- 2007-09-12 UY UY30587A patent/UY30587A1/es not_active Application Discontinuation
- 2007-09-13 PL PL07802300T patent/PL2066647T3/pl unknown
- 2007-09-13 CA CA002660987A patent/CA2660987A1/en not_active Abandoned
- 2007-09-13 JP JP2009527741A patent/JP5325105B2/ja not_active Expired - Fee Related
- 2007-09-13 EP EP07802300A patent/EP2066647B1/en active Active
- 2007-09-13 PE PE2007001237A patent/PE20080842A1/es not_active Application Discontinuation
- 2007-09-13 ES ES07802300T patent/ES2377148T3/es active Active
- 2007-09-13 EA EA200900388A patent/EA200900388A1/ru unknown
- 2007-09-13 CN CN2007800339907A patent/CN101516860B/zh not_active Expired - Fee Related
- 2007-09-13 AU AU2007296916A patent/AU2007296916B2/en not_active Ceased
- 2007-09-13 AR ARP070104060A patent/AR062786A1/es unknown
- 2007-09-13 BR BRPI0716841-1A2A patent/BRPI0716841A2/pt not_active IP Right Cessation
- 2007-09-13 PT PT07802300T patent/PT2066647E/pt unknown
- 2007-09-13 MX MX2009002812A patent/MX2009002812A/es active IP Right Grant
- 2007-09-13 AT AT07802300T patent/ATE532774T1/de active
- 2007-09-13 KR KR1020097005248A patent/KR20090064389A/ko not_active Application Discontinuation
- 2007-09-13 US US12/440,298 patent/US8629168B2/en not_active Expired - Fee Related
- 2007-09-13 WO PCT/EP2007/007983 patent/WO2008031594A1/en active Application Filing
- 2007-09-14 TW TW096134606A patent/TW200819444A/zh unknown
- 2007-09-14 PA PA20078748101A patent/PA8748101A1/es unknown
- 2007-09-14 CL CL200702669A patent/CL2007002669A1/es unknown
-
2009
- 2009-01-21 ZA ZA200900477A patent/ZA200900477B/xx unknown
- 2009-02-02 IL IL196860A patent/IL196860A0/en unknown
- 2009-02-26 CR CR10639A patent/CR10639A/es not_active Application Discontinuation
- 2009-02-27 TN TN2009000070A patent/TN2009000070A1/fr unknown
- 2009-03-10 CO CO09024347A patent/CO6150142A2/es unknown
- 2009-03-11 GT GT200900056A patent/GT200900056A/es unknown
- 2009-03-30 MA MA31738A patent/MA30723B1/fr unknown
- 2009-04-09 SM SM200900023T patent/SMP200900023B/it unknown
- 2009-04-15 NO NO20091469A patent/NO20091469L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
| PA8680701A1 (es) | Derivados de oxindol | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| ECSP099387A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
| CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
| DOP2010000013A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| PA8587101A1 (es) | Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos | |
| ECSP088828A (es) | 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r | |
| ECSP088869A (es) | Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica | |
| UY29093A1 (es) | Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones. | |
| ECSP10010427A (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET | |
| ECSP055899A (es) | Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos | |
| MXPA05012573A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa. | |
| UY29300A1 (es) | Compuestos quimicos | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| GT200800148A (es) | Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal. | |
| GT200600089A (es) | Compuestos organicos | |
| SV2007002007A (es) | Compuestos de quinolina sustituidos ref. pc 25932a | |
| PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| UY31805A (es) | Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor | |
| UY30705A1 (es) | Sulfonamidas sustituidas | |
| CL2004000631A1 (es) | Compuestos derivados del acido 6-(2-bromofenil)-pirido[2,3-dipirimidin-7-carboxilico; composicion farmaceutica; procedimiento de preparacion; y uso para tratar el cancer y para preparar medicamentos para inhibir el crecimiento tumoral. | |
| ECSP088968A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia |